Novartis Number of Shares Shorted

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>NO</div>
NVS -- USA Stock  

Report: 21st of July 2020  

Novartis number of shares shorted fundamental analysis lookup allows you to check this and other indicators for Novartis AG or any other equity instrument. You can also select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please continue to Equity Screeners to view more equity screening tools

Search Number of Shares Shorted

 
Refresh
As of 07/14/2020, Weighted Average Shares is likely to grow to about 2.6 B, while Issuance Purchase of Equity Shares is likely to drop (5.5 B).

Novartis Number of Shares Shorted Analysis

Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
 2017 2019 (projected)
Book Value per Share31.2424.0
Asset Turnover0.330.37
Shares Shorted 
 = 
Shorted by Public 
by Institutions 
More About Number of Shares Shorted | All Equity Analysis

Current Novartis AG Number of Shares Shorted

2.56 M

Novartis Distress Driver Correlations

About Number of Shares Shorted

If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Compare to competition

  Consolidated Income

Based on the recorded statements Novartis AG has 2.56 M of outstending shares currently sold short by investors. This is 19.98% lower than that of the Healthcare sector and significantly higher than that of Drug Manufacturers?General industry. The number of shares shorted for all United States stocks is 45.59% higher than that of the company.

Novartis Number of Shares Shorted Peer Comparison

  Number of Shares Shorted 
      Novartis Comparables 
Novartis is rated below average in number of shares shorted category among related companies.

NovartisCurrent Valuation Drivers

2014201520162017201820192020 (projected)
Average Assets125.82 B128.47 B130.84 B131.6 B139.32 B131.97 B140.55 B
Earnings before Tax11.76 B18.89 B7.83 B9.31 B13.91 B13.53 B13.89 B
Average Equity72.55 B73.91 B75.94 B74.5 B76.39 B67.04 B75.19 B
Enterprise Value236.13 B213.77 B190.17 B216.12 B218.53 B237.72 B236.29 B
Free Cash Flow11.33 B9.77 B9.77 B11.39 B13.12 B13.1 B13.51 B
Invested Capital52.66 B59.71 B62.39 B67.6 B60.82 B53.02 B60.88 B
Tangible Asset Value72.24 B66.17 B67.8 B71.33 B71.55 B63.06 B71.58 B
Working Capital10.59 B(863 M)2.72 B4.8 B5.96 B1.24 B1.27 B
Book Value per Share29.1732.1231.5231.2433.9224.029.65
Current Ratio1.161.390.961.121.211.21.05
Debt to Equity Ratio0.70.770.710.740.851.131.06
Dividend Yield0.0310.0290.0280.0380.0260.140.15
Payout Ratio0.650.320.980.710.412.632.84
Price to Book Value3.182.682.312.692.533.953.57
Price to Sales Ratio4.194.13.54.594.314.54.44
Sales per Share22.1121.0120.8318.2819.8921.0620.09
Capital Expenditure(2.56 B)(2.13 B)(1.7 B)(1.23 B)(1.15 B)(522 M)(563.21 M)

Novartis Fundamentals

About Novartis Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Novartis AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novartis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novartis AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way. Please read more on our fundamental analysis page.
 2017 2018 2019 2020 (projected)
Current Assets28.21 B35.56 B29.5 B32.46 B
Total Assets133.08 B145.56 B118.37 B134.45 B


 
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page